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Abstract To characterize Ser 1°29 in STaR at a consensus 
sequence of phosphorylation site by PKC, two mutants of 
mS1029A with replacement of Ser 1°29 to Ala 1029 and CA1029 
lacking 22 amino acids including Ser 1029 were prepared. 
Preincnhation of the wild type-STaR (wt-STaR) transfectant 
with 1 gM PMA caused additional STa-mediated gnanylyl 
cydase (GC) activation compared to control, whereas the 
mS1029A- and CA1029-transfected cells did not show a similar 
enhanced GC activation by PMA. After metabolic labeling with 
[32p]phosphate, transfected cells with wt-STaR and mutants were 
incubated with 1 gM PMA. Subsequent 32p-radiolabeled 
proteins were immunoprecipitated using anti-STaR antibody, 
and analyzed by autoradiography after separation on SDS- 
PAGE. The immunoprecipitated wt-STaR but not mS1029A and 
CA1029 had a significant radioactivity. These results suggest 
that the effect of PMA on wt-STaR transfectants may be caused 
by phospborylation of Ser 1°29. The CA1012 mutant, with further 
truncation (Glnl°12-Pbe 1°5°) of the carboxy terminus, did not 
show STa-mediated GC activation. Based on these data, these 17 
amino acids (Gln1°12-Ala1°2s), essential for signaling of GC 
activation by STa, have an abundance of basic amino acids which 
might be functionally influenced by phosphorylation of Ser 1°29. 
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1. Introduction 
fibrosis-related chloride channels possibly by activation of 
protein kinase A [7]. STaR has common structural features 
among membrane-associated GCs, including an extracellular 
ligand-binding domain, a single transmembrane domain, a 
kinase-homology domain and a GC catalytic domain. In a 
prolonged carboxy-terminal t il adjacent to the GC catalytic 
domain, STaR has an extra 63 or 62 amino acids compared to 
the natriuretic peptide receptors, NPR-A/GC-A or NPR-B/ 
GC-B (Fig. 1). 
In the T84 colonic carcinoma intestinal cell line, phorbol 
esters have an additive effect on STa-stimulated GC activity 
consistent with a possible role for phosphorylation by protein 
kinase C (PKC) [8]. It is notable that this activation effect of 
phorbol myristate acetate (PMA) on STa-stimulated GC ac- 
tivity of STaR is opposite to the inhibitory effects of PMA on 
NPR-A-stimulated GC activity [9-12]. More recently, Crane 
et al. have demonstrated that phosphorylation of STaR is 
blocked by addition of a synthetic peptide, KPRRVA- 
SYKKG, corresponding to the sequence around Set 1°29 in 
the carboxy-terminal t il of the STAR, suggesting the putative 
phosphorylation site to be Ser 1°29 (personal communication). 
Here, we report the significance of phosphorylation f Ser 1°29 
of STaR in mediating signaling by PMA by using various 
mutants of pig STAR. We describe that a CA1012 mutant, 
which has the GC catalytic domain and lacks 39 amino acids 
in the C-terminus of STAR, loses its inherent properties to be 
activated by STa. 
The heat-stable enterotoxin (STa) of Escherichia coli is an 
18 or 19 amino acid peptide toxin (STp or STh) that causes 
diarrhea in humans and domestic animals [1,2]. STa binds to a 
cell surface receptor (STaR/GC-C) [3-6] in the intestine, 
which subsequently leads to activation of a guanylyl cyclase 
(GC) catalytic domain resulting in an accumulation of intra- 
cellular cyclic GMP (cGMP). The increase in cGMP causes 
fluid secretion, in part, through the phosphorylation f cystic 
*Corresponding author. Fax: (81) (958) 49-7805. 
Abbreviations: STa, heat-stable enterotoxin; STh, heat-stable enter- 
otoxin produced by a human strain of Escherichia coli; STAR, heat- 
stable nterotoxin receptor; GC, guanylyl cyclase; PMA, phorbol 12- 
myristate 13-acetate; PKC, protein kinase C; SDS, sodium dodecyl 
sulfate; PAGE, polyacrylamide g l electrophoresis; DMEM, Dulbec- 
co's modified Eagle's medium. 
2. Materials and methods 
2.1. Star mutant constructs 
The pCG-STaR which contains the full-length pig STaR cDNA [6] 
under the cytomegalovirus promoter [13] was used for this study as 
wild-type STaR (wt-STaR). A STaR point mutant, mS1029A was 
constructed using an oligonucleotide (5'-CA ACC CGG GTA GCC 
GCA TAC AAG AAA GGC A-3') according to Kunkel [14]. STaR 
deletion mutant cDNAs were constructed by the use of polymerase 
chain reaction. 
2.2. lntracellular cGMP determination 
293T cells are a human embryonic kidney cell line infected with 
adenovirus carrying an SV40-1arge T-antigen expression plasmid 
[15]. The cells were grown in DMEM medium supplemented with 
10% fetal calf serum. The cells were transfected with 10 gg of the 
pCG mammalian expression vector in which we inserted the pig 
STaR gene (pCG-STaR) or its mutated gene as reported in [6]. Trans- 
fection was accomplished using the calcium phosphate method [16]. 
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Fig. 1. STaR mutant constructs in carboxy-terminal regions. 
cGMP assays were done as described previously [6] using a radio- 
immunoassay kit (Yamasa cGMP assay kit, Yamasa, Japan). 
2.3. Preparation of anti-STaR and immunoprecipitation of recombinant 
STaR 
A synthetic peptide, CTNHVSLKIDDDRRRD (amino acids 461- 
475 with an additional amino-terminal Cys residue), representing the 
begining of the kinase-homology domain of pig STaR [6] was synthe- 
sized and coupled to bovine serum albumin. Rabbits were immunized 
subcutaneously with the antigen. The antiserum with the highest iter 
in enzyme-linked immunosorbent assay, GCINT1, was used in this 
study after determination f its specificity against recombinant STaR 
using Western blot analysis. Metabolic labeling and immunoprecipi- 
taion of STaR and its mutants with [a~S]methionine, [aSS]cysteine, and 
[32p]phosphate were performed according to Vaandrager et al. [17]. 
The STa used here is a synthesized STh reported in [18]. Other re- 
agents were of analytical grade. 
3. Results  and discussion 
To characterize the role of Ser 1°29 in STAR, two mutated 
genes encoding a mS1029A with substitution at Ser 1°29 to 
Ala 1°29 and CA1029 deleted with Ser 1°29 to the carboxy-term- 
inal amino acid Phe 1°5° were constructed (Fig. 1). When the 
mS1029A- and CA1029-transfected cells were incubated with 
1 I.tM STa for 10 min, the intracellular cGMP concentration 
of the transfected cells increased in a manner similar to wt- 
STaR transfectants (Fig. 2). Pretreatment of the wt-STaR 
transfectants with 1 IxM PMA for 10 min prior to the addition 
of STa in the culture medium provoked a more potent stimu- 
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Fig. 2. Effect of PMA on GC activity in STaR or its mutants ex- 
pressing 293T cells. STaR expressed 293T cells were treated with or 
without PMA for 10 min at 37°C, and then were treated with 1 ~tM 
STa. 
latory effect of STa on GC activity of wt-STaR (Fig. 2). This 
is similar to the results previously shown by Weikel et al. [8]. 
However, this additive effect of PMA was not observed in the 
mS1029- and CA1029-transfected cells (Fig. 2). These results 
suggest hat Ser 1°29 in the carboxy-terminal tail of wt-STaR 
may be a phosphorylation site by PKC resulting from treat- 
ment with PMA, and that the phosphorylated Ser 1°29 induced 
a suitable conformational change in the GC catalytic domain 
which in turn led to the more active form. 
We investigated further the possible phosphorylation of 
Ser 1°z9 addressing the suspicion that mS1029A and CA1029 
were not expressed on the transfected cells by metabolic label- 
ing with [35S]methionine and [3~S]cysteine. Fig. 3A shows that 
mS1029A and CA1029 mutants were expressed in the trans- 
fected cells at a rate similar to those of wt-STaR and three 
carboxy-terminal tail deletion mutants (CA988, CA996, and 
CA1012, Fig. 1) by imunoprecipitation analysis after meta- 
bolic labeling proteins with [aSS]methionine and [a~S]cysteine. 
After preincubation of the wt-STaR transfectants and mu- 
tants with [32P]phosphoric acid for 3 h and subsequent treat- 
ment with 1 ktM PMA for 1 h, the 32p-labeled STaR and the 
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Fig. 3. Metabolic labeling of STaR or its mutants. (A) Immunopre- 
cipitations of 35S-labeled STaR or its mutants using anti-STaR anti- 
body, GCINT1. (B) Immunoprecipitations of 32p-labeled STaR or 
its mutants incubated with or without PMA for 1 h. 
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Fig. 4. cGMP production in response to STh(1-19) by STaR or its 
mutants. 293T cells transfected with the indicated genes (10 gg) 
were treated with or without 1 I.tM STa for 10 rain at 37°C. Results 
are expressed asthe mean + S.E.M. of four determinations. 
mutants were immunoprecipitated using anti-STaR antibody, 
GCINT1 (Fig. 3B). No significant radioactive incorporation 
into the two mutants mS1029A and CA1029 was observed, 
even though wt-STaR was detected as a radioactive band 
on the SDS-PAGE gel. Three carboxy-terminal deletion mu- 
tants lacking Ser 1°29 also did not incorporate 32p radioactiv- 
ity. This result strongly suggests Ser 1°29 is a target site of 
phosphorylation by PKC because the two mutants 
mS1029A and CA1029 lacked Ser 1°29 by amino acid substitu- 
tion or deletion, respectively. This result is also consistent 
with the presence of a PKC consensus phosphorylation se- 
quence (RXXSXK) surrounding Ser 1°29 (RVASYK) [19]. 
To understand the importance of the carboxy terminus in 
the STa-mediated reaction of GC and in the modulation of 
the effects of STa by PKC, further examination compares the 
effects of other deletions of the carboxy-terminal t il on STa- 
induced GC-activation using CA988, CA996, CA1012, and 
CA1029 (Fig. 1). When the CA1029 transfected cells were in- 
cubated with 1 ~tM STa for l0 min, intracellular cGMP con- 
centration increased at a similar level to that in wt-STaR as 
shown in Fig. 4. However, no increase in STa-mediated in- 
tracellular cGMP was observed in the cells transfected with 
CA988, CA996, and CA1012. As shown in Fig. 3A, CA988, 
CA996, and CA1012 were expressed at similar levels to wt- 
STaR in 293T cells as judged by immunoprecipitation. All 
mutant constructs showed similar levels of cell surface xpres- 
sion as wt-STaR by immunofluorescence staining (data not 
shown). These results suggest hat 22 amino acid residues 
(Serl°29-Phe 1°5°) including Ser 1°29 at the carboxy-terminal 
tail of STaR are not required for STa-mediated GC activa- 
tion. STa-mediated activation of the GC domain occurs with- 
out phosphorylation f Ser 1°29. However, further activation of 
STaR by pretreatment with PMA before exposure to STa 
might be due to phosphorylation of Ser 1°29. The sequence 
consisting of 17 amino acids at positions 1012-1028 adjacent 
to Ser ~°29 has an abundance of basic amino acids such as Arg 
or Lys residues. This sequence may functionally affect the 
ability of STa to activate the GC catalytic domain. The mu- 
tant CA1012 lacking these 17 amino acids at 1012-1028 lost 
its inherent property of STa-mediated GC activation even 
though CA1012 could bind to STa, indicating that this dele- 
tion mutation inactivated catalytic function. Phosphorylation 
of Ser 1°29 may introduce an ionic interaction between the 
phosphoric acid and these basic amino acids, which in turn 
allows it to be in a more reactive state and generate an ex- 
aggerated response to STa. These data support he schema 
proposed by Weikel et al. [8]. Rudner et al. [20] recently pro- 
posed that the binding of STa to STaR removes the inhibitory 
effects of the kinase-homology domain and promotes an inter- 
action between GC catalytic domains. It is therefore likely 
that the 17 amino acids at 1012-1028 play a role in the inter- 
action of GC catalytic domain or the kinase-homology do- 
main. More extensive analysis of these 17 amino acids is pres- 
ently under way. 
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